Anzurstobart
Anzurstobart (CC-95251; BMS-986351) is a high-affinity, fully human monoclonal anti-SIRPα antibody that blocks the binding of CD47 to SIRPα. Anzurstobart enhances macrophage phagocytic activity against DLBCL cell lines in co-culture models when combined with the antibody Rituximab (HY-P9913) . Anzurstobart has the potential for solid and hematologic malignancies research[1].
Product Specifications
CAS Number
[2543693-10-1]
Product Name Alternative
CC-95251; BMS-986351
UNSPSC
12352203
Target
CD47
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/anzurstobart.html
Purity
98.53
Solubility
10 mM in DMSO
Smiles
[Anzurstobart]
Molecular Weight
(144.66 kDa)
References & Citations
[1]Henry Chan, et al. Discovery and Preclinical Characterization of CC-95251, an Anti-SIRPα Antibody That Enhances Macrophage-Mediated Phagocytosis of Non-Hodgkin Lymphoma (NHL) Cells When Combined with Rituximab. Blood (2021) 138 (Supplement 1) : 2271.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
